Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Week in Review

Summaries of each week's events in China biotech are provided free to all readers.  A weekly email newsletter providing direct links to these articles is also available - click here for free email newsletter...

Week in Review: Sino Biopharm Subsidiary Enters $307 Million Agreement for Rights to NASH Candidate

Week in Review: METiS, a US-China AI biotech, Acquires Pan-RAF Inhibitor in $482 Million Deal

Week in Review: Beijing BoomRay Closes $43 Million A Round for Novel Radionuclide Drugs

Week in Review: Biocytogen, a Genetically Modified Animal Models Company, Stages $60 Million IPO

Week in Review: China and the US May Settle De-Listing/Accounting Impasse

ChinaBio Event
Beijing and Digital
November 8-11, 2022
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
July 27-31, 2022